A Randomized Phase III Double Blinded Placebo-Controlled Trial of Aspirin as Adjuvant Therapy for Node-Positive, HER2 Negative Breast Cancer: The ABC Trial

March 21, 2017
ABC Trial (A011502)
Breast Cancer
Samir Undevia, MD
Edward Cancer Center - Naperville
Edward Cancer Center - Plainfield
Nancy Knowles Cancer Center - Elmhurst

To compare any good and bad effects of using aspirin after someone has completed the usual chemotherapy, surgery and/or radiation therapy for breast cancer. This study will evaluate whether patients taking aspirin once per day will have a lower rate of cancer recurrence than patients taking a placebo.

Sponsor: Alliance for Clinical Trials in Oncology


  • Node positive, HER2 negative, anatomic stage II or III breast carcinoma within 1 year of diagnosis and free of recurrence
  • Any ER/PgR status allowed
  • Age > 18 and < 70 years of age
  • No history of GI bleeding
  • No history of any prior stroke
  • No concurrent anticoagulation, no history of atrial fibrillation or myocardial infarction

10 years

Accepting Participants
Kathy Seymour, BSN